Following the approval of monoclonal antibodies Leqembi and Kisunla, investment and mergers in Alzheimer's disease therapies surged by 780% from 2022 to 2024. This renewed momentum has prompted large pharmaceutical companies like AbbVie and Sanofi to pursue high-value acquisitions, focusing on efficacy improvements, safety, and novel targets beyond amyloid-beta. Despite challenges in market adoption and sales, this wave reinvigorates research and development in neurodegenerative disease treatments.